|
1) Irie J, Wu Y, Wicker L, et al. NOD. c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med. 2006; 203: 1209
|
|
|
|
2) Oertelt S, Lian Z, Cheng C, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol. 2006; 177: 1655
|
|
|
|
|
|
3) Wakabayashi K, Lian Z, Moritoki Y, et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology. 2006; 44: 1240
|
|
|
|
|
|
4) Ueno Y, Moritoki Y, Shimosegawa T, et al. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol. 2007; 42: 189
|
|
|
|
|
5) Shimoda S, Ishikawa F, Kamihira T, et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology. 2006; 131: 606
|
|
|
|
|
|
6) Wang A, Migita K, Ito M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun. 2005; 25: 85
|
|
|
|
|
|
7) Mao T, Lian Z, Selmi C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology. 2005; 42: 802
|
|
|
|
|
|
8) Yokoyama T, Komori A, Nakamura M, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int. 2006; 26: 467
|
|
|
|
|
|
9) Moritoki Y, Lian Z, Wulff H, et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology. 2007; 45: 314
|
|
|
|
|
|
10) Honda Y, Yamagiwa S, Matsuda Y, et al. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol. 2007; Epub ahead of print
|
|
|
|
|
|
11) Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005; 42: 386
|
|
|
|
|
|
12) Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007; 45: 118
|
|
|
|
|
|
13) Murata Y, Abe M, Furukawa S, et al. Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices. J Gastroenterol. 2006; 41: 1220
|
|
|
|
|
|
14) Wong G, Hui A, Wong V, et al. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol. 2005; 100: 2205
|
|
|
|
|
|
15) Wong R, Lim S, Wee A, et al. Primary biliary cirrhosis in Singapore: Evaluation of demography, prognostic factors and natural course in a multi-ethnic population. J Gastroenterol Hepatol. 2007; Epub ahead of print
|
|
|
|
|
|
16) Sarin S, Monga R, Sandhu B, et al. Primary biliary cirrhosis in India. Hepatobiliary Pancreat Dis Int. 2006; 5: 105
|
|
|
|
|
|
17) Speiciene D, Irnius A, Leuschner U, et al. Primary biliary cirrhosis in Lithuania: Diagnosis and clinical picture. Med Sci Monit. 2007; 13: CR299
|
|
|
|
|
|
18) Peters M, Di Bisceglie A, Kowdley K, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology. 2007; Epub ahead of print
|
|
|
|
|
|
19) 石橋大海. 日本人原発性胆汁性肝硬変患者のQOLをどう評価するか？ 肝臓. 2007; 48: 253-5
|
|
|
|
|
20) Stanca C, Bach N, Krause C, et al. Evaluation of fatigue in U. S. patients with primary biliary cirrhosis. Am J Gastroenterol. 2005; 100: 1104
|
|
|
|
|
|
21) Blackburn P, Freeston M, Baker C, et al. The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int. 2007; 27: 654
|
|
|
|
|
|
22) Jones D, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006; 55: 536
|
|
|
|
|
|
23) Jones D, Newton J. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007; 25: 471
|
|
|
|
|
|
24) Fisk J, Ritvo P, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994; 18: S79
|
|
|
|
|
|
25) Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005; 54: 1622
|
|
|
|
|
|
26) Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006; 130: 715
|
|
|
|
|
|
27) ter Borg P, Schalm S, Hansen B, et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006; 101: 2044
|
|
|
|
|
|
28) Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006; 102: 464
|
|
|
|
|
|
29) Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: An updated systematic review and meta-analysis of randomized clinical trials using Bayesian Approach as sensitivity analyses. Am J Gastroenterol. 2007; Epub ahead of print
|
|
|
|
|
|
30) Yan G, Erik C, Gluud C. The long-term beneficial effects of ursodeoxycholic acid in primary biliary cirrhosis are highly questionable. Am J Gastroenterol. 2007; 102: 464
|
|
|
|
|